As a global biotech leader, Amgen supports a vast and diverse portfolio of brands—many of which leverage combination devices and biosimilars. The Patient Strategy Department, a cross-functional initiative within Amgen, needed a scalable, compliant, and patient-centered framework for educating patients across multiple therapeutic areas. Given the complexity of self-injectables, biosimilars, and global regulatory needs, Amgen sought a strategic partner to help unify and elevate their patient education strategy and materials.

Following the acquisition of Volcano Corporation, Philips needed to rapidly integrate an extensive portfolio of vascular intervention products into its corporate brand framework. Beyond brand transition, Philips faced the challenge of educating both healthcare providers and patients about peripheral arterial disease (PAD), a highly underdiagnosed condition. The goal was twofold: standardize product assets under Philips’ global brand and build a multi-tiered education platform to support awareness, diagnosis, and treatment pathways for PAD.